Clinical trial
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions: A Prospective, Open-Label, Exploratory Study
NCT07888335 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions: A Prospective, Open-Label, Exploratory Study
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- December 10, 2026
- Completion date
- December 30, 2028
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary iga nephropathy
Lead sponsor's other trials
Ruijin Hospital, most recent start first.
+673 more trials See the organization page
Similar trials
Same condition (Glomerulonephritis, IGA) and phase, most recent start first.
+26 more trials See the condition page